{"name":"Mochida Pharmaceutical","slug":"mochida","ticker":"4534.T","exchange":"TSE","domain":"mochida.co.jp","description":"Mochida Pharmaceutical Co., Ltd  is a Japanese pharmaceutical company.","hq":"Tokyo, Japan","founded":1933,"employees":"1508","ceo":"Junichi Mochida","sector":"GI / Women\\","stockPrice":3535,"stockChange":110,"stockChangePercent":3.21,"marketCap":"$125.3B","metrics":{"revenue":111914999808,"revenueGrowth":9.7,"grossMargin":48.4,"rdSpend":0,"netIncome":6422000128,"cash":41497001984,"dividendYield":2.34,"peRatio":18.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2010-01-01","label":"Natazia first approved","drug":"Natazia","drugSlug":"dienogest","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Mochida Pharmaceutical's Gastrointestinal Drug patent cliff ($1.2B at risk)","drug":"Mochida Pharmaceutical's Gastrointestinal Drug","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Icosapent (MND-2119)","genericName":"Icosapent (MND-2119)","slug":"icosapent-mnd-2119","indication":"Hypertriglyceridemia in patients with elevated cardiovascular risk","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Natazia","genericName":"DIENOGEST","slug":"dienogest","indication":"Contraception","status":"marketed"}]}],"pipeline":[{"name":"Icosapent (MND-2119)","genericName":"Icosapent (MND-2119)","slug":"icosapent-mnd-2119","phase":"phase_3","mechanism":"Icosapent is a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism.","indications":["Hypertriglyceridemia in patients with elevated cardiovascular risk"],"catalyst":""},{"name":"Natazia","genericName":"DIENOGEST","slug":"dienogest","phase":"marketed","mechanism":"Natazia works by binding to the progesterone receptor in the body, mimicking the effects of the natural hormone progesterone.","indications":["Contraception","Dysmenorrhea"],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Mochida Pharmaceutical Reports FY2023 Earnings","summary":"The company reported a net income of ¥10.3 billion for the fiscal year 2023, up 12% from the previous year.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"deal","headline":"Mochida Pharmaceutical Partners with [Partner Company] for New Drug Development","summary":"The partnership aims to develop a new treatment for gastrointestinal disorders.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNQWx3QlIycXpBLXdEeTJHTGhkTUM3N0J2cDBDRjJ6TnZjUXBXLV9vOXRlQ25lY081MkxqN1ZSRjNpUHdoZ0lsTWdyeXlWSzREQkNpeUlZX0REbmFWRE4yNXZTbWplSlBHenVpYW9VekhBX0lKYjl4R3d4a1ViVGNxYnBlVGVpWTNxR3lRTGJUVm1mSTBUTG5CcjJQN2ljUFdSeEhrNzkwSG03RUMzRy16YngzVFN0dVRISVhBb1VGQTRYWXpITFEwRlM4S2ZSM1BBc0E?oc=5","date":"2026-03-30","type":"earnings","source":"TipRanks","summary":"Mochida Pharma Clears Audit Review as Profits Rise Ahead of Secondary Share Offering - TipRanks","headline":"Mochida Pharma Clears Audit Review as Profits Rise Ahead of Secondary Share Offering","sentiment":"positive"}],"patents":[{"drugName":"Mochida Pharmaceutical's Gastrointestinal Drug","drugSlug":"generic-name","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Takeda Pharmaceutical","Eisai Co., Ltd.","Otsuka Holdings Co., Ltd."],"therapeuticFocus":["Gastrointestinal","Women's Health"],"financials":null,"yahoo":{"currentPrice":3535,"previousClose":3425,"fiftyTwoWeekHigh":3965,"fiftyTwoWeekLow":2836,"fiftyTwoWeekRange":"2836.0 - 3965.0","fiftyDayAverage":3674.9,"twoHundredDayAverage":3324.51,"beta":0,"enterpriseValue":89918939136,"forwardPE":18.9,"priceToBook":0.91,"priceToSales":1.12,"enterpriseToRevenue":0.8,"enterpriseToEbitda":7.85,"pegRatio":0,"ebitda":11448999936,"ebitdaMargin":10.2,"freeCashflow":0,"operatingCashflow":0,"totalDebt":10000000000,"debtToEquity":7.3,"currentRatio":4.01,"returnOnAssets":3,"returnOnEquity":4.8,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":80,"payoutRatio":0.42,"fiveYearAvgDividendYield":2.44,"exDividendDate":1774828800,"insiderHeldPercent":36.5,"institutionHeldPercent":15,"sharesOutstanding":35450203,"floatShares":23195584,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":189.4,"epsForward":187.2,"revenuePerShare":3156.95,"bookValue":3876.74,"officers":[{"age":67,"name":"Mr. Naoyuki  Mochida","title":"President & Chairperson"},{"age":null,"name":"Masaaki  Yokosuka","title":"Executive Officer and Legal & Compliance Manager"},{"age":65,"name":"Mr. Junichi  Sakaki Ph.D.","title":"Senior Executive Managing Officer & Representative Director"},{"age":66,"name":"Yutaka  Kawakami Ph.D.","title":"Managing Executive Officer & Executive Director"},{"age":null,"name":"Tomokazu  Matsusue","title":"Managing Executive Officer & Head of Business Development Division"},{"age":null,"name":"Hitoshi  Mizuno","title":"Managing Executive Officer & GM of Medical Device Product Development"},{"age":null,"name":"Junichi  Makino","title":"Executive Officer Deputy Head of Pharmaceutical Sales Division"},{"age":null,"name":"Taiji  Hayano","title":"GM of Pharmaceutical Development Division & Managing Executive Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.mochida.co.jp","phone":"81 3 3358 7211"}}